Demo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase onlyDemo mode: simulated data, for showcase only
Counts new disease-modifying Alzheimer's therapies approved beyond lecanemab and donanemab. Resolves to the bucket matching the FDA total for 2026. Source: FDA.
FDA novel Alzheimer's approvals in 2026?
